rethinkPeptides Search
Menu
Study breakdown

Computer Models Predict Which Lactoferricin Variants Will Best Kill Herpes Virus

In VitroPreliminary evidence
The takeaway

Amino acid descriptor-based computational models predicted anti-herpes activity of lactoferricin analogs, enabling rational design of more potent antiviral peptide variants without exhaustive synthesis.

Key finding

QSAR modeling using amino acid descriptors predicted anti-HSV activity of lactoferricin analogs, identifying structural features correlated with antiv

What the researchers found

QSAR modeling using amino acid descriptors predicted anti-HSV activity of lactoferricin analogs, identifying structural features correlated with antiviral potency and enabling computational design of optimized anti-herpes peptides.

Why it matters

Relevant for antimicrobial-peptides, infection, peptide-design.

How the study worked

in-vitro study on antimicrobial-peptides, infection.

What this study cannot tell us

See abstract.

How to read the evidence

preliminary evidence.

When this study was published

Published in 2005.

The bigger picture

Advances peptide research with clinical implications.

Questions still open

  • Further research needed.
  • Clinical translation to evaluate.

Common questions

What was studied?
Computer Models Predict Which Lactoferricin Variants Will Best Kill Herpes Virus
What was found?
Amino acid descriptor-based computational models predicted anti-herpes activity of lactoferricin analogs, enabling rational design of more potent antiviral peptide variants without exhaustive synthesis.

Read the original research

Modelling of anti-HSV activity of lactoferricin analogues using amino acid descriptors.

Journal of peptide science : an official publication of the European Peptide Society, 11(2), 97-103

Citation

Jenssen, Håvard; Gutteberg, Tore J; Lejon, Tore. (2005). Modelling of anti-HSV activity of lactoferricin analogues using amino acid descriptors.. Journal of peptide science : an official publication of the European Peptide Society, 11(2), 97-103.